Immunotherapy in Triple-Negative Breast Cancer.
Journal
Cancer journal (Sudbury, Mass.)
ISSN: 1540-336X
Titre abrégé: Cancer J
Pays: United States
ID NLM: 100931981
Informations de publication
Date de publication:
Historique:
entrez:
21
1
2021
pubmed:
22
1
2021
medline:
28
9
2021
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free survival benefit in metastatic programmed death ligand-1 (PD-L1)-positive TNBC patients treated first line. Based on IMpassion130, the combination of atezolizumab and nab-paclitaxel is now considered a standard of care for the treatment of PD-L1-positive advanced TNBC. In early TNBC, pembrolizumab and atezolizumab have been tested in combination with standard neoadjuvant chemotherapy, resulting in a higher complete pathologic response rate than standard neoadjuvant chemotherapy alone, regardless of disease PD-L1 status. These findings establish proof of principle for immunotherapy in both early and advanced TNBC. High priorities for the field include developing more active immunotherapy combination regimens and more refined biomarkers that optimally identify patients most likely to benefit from immunotherapy.
Identifiants
pubmed: 33475294
doi: 10.1097/PPO.0000000000000497
pii: 00130404-202101000-00009
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-66Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Sources of Funding: L.A.E. is cochair of the steering committee for the IMpassion130 study and chair of the KATE2 study steering committee; reports honoraria from AbbVie, Amgen, Celgene, Chugai, Gilead, Gritstone, GPCR, MedImmune, Peregrine, Shionogi, and Syndax; honoraria and travel support from AstraZeneca, Bayer, MacroGenics, Replimune, and Vaccinex; travel support from Bristol-Myers Squibb, Genentech/Roche, and Novartis; has potential future stock from MolecuVax; reports institutional support from Aduro Biotech, AstraZeneca, the Breast Cancer Research Foundation, Bristol-Myers Squibb, Bolt Therapeutics, Corvus, the US Department of Defense, EMD Serono, Genentech, MaxCyte, Merck, the National Cancer Institute, the NSABP Foundation, Roche, Silverback, the Translational Breast Cancer Research Consortium, Tempest, and HeritX; and reports royalties from Aduro.
Références
Malhotra MK, Emens LA. The evolving management of metastatic triple negative breast cancer. Semin Oncol. 2020;47:229–237.
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractor metastatic triple negative breast cancer. N Engl J Med. 2019;380:741–751.
Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor–positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;X0923–7534:42445–42447.
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.
Emens LA, Adams S, Barrios CH, et al. IMpassion 130: final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Abstract LBA16. Presented at ESMO Virtual Congress 2020; September 19, 2020.
Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–520.
Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686.
Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase 1b KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–2467.
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–404.
Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1–positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–411.
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow up: a phase 1b clinical trial. JAMA Oncol. 2019;5:334–342.
Miles DW, Gligorov J, Andre F, et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel +/− atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Abstract LBA15. Presented at ESMO Virtual Congress 2020; September 19, 2020.
Cortes J, Lipatov O, Im S, et al. KEYNOTE-119: phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2019;30(suppl 5):v851–v934.
Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol. 2020;38(suppl 15):1000.
Adams S, Dieras V, Barrios CH, et al. Patient-reported outcomes from the phase III Impassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31:582–589.
Emens LA, Loi S, Rugo HS, et al. IMpassion130: efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally-advanced or metastatic triple negative breast cancer [abstract]. Cancer Res. 2019;79(suppl 4): Abstract nr GS1-04.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–821.
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion 031): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020;S0140–6736:31953–X.
Gianni L, Huang C-S, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer: NeoTRIPaPDL1 Michelangelo randomized study [abstract GS3-04]. Cancer Res. 2019;79(suppl 13): abstract nr GS3-04.
Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11–22.
Rugo HS, Olopade O, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23–34.
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6:1–9.
Campbell MJ, Yau C, Bolen J, et al. Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY2 trial [abstract CT003]. Cancer Res. 2019;79(suppl 13): abstract nr CT003.
Liu MC, Robinson PA, Yau C, et al. Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk, early stage HER2-negative breast cancer: results from the I-SPY2 trial [abstract P3-09-02]. Cancer Res. 2020;80(suppl 4): abstract nr P3-09-02.
Pusztai L, Han HS, Yau C, et al. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2-negative stage II/III breast cancer: results from the I-SPY2 trial [abstract CT011]. Cancer Res. 2020;80(suppl 4): abstract nr CT011.
Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279–1288.
Karn T, Denkert C, Weber KE, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;S0923–7534:39836–39837.